{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:31:51Z","timestamp":1793417511159,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004561","name":"Ministry of Education and Science of the Republic of Kazakhstan","doi-asserted-by":"publisher","award":["AP05131463"],"award-info":[{"award-number":["AP05131463"]}],"id":[{"id":"10.13039\/501100004561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A new candidate vector vaccine against human brucellosis based on recombinant influenza viral vectors (rIVV) subtypes H5N1 expressing\n                      <jats:italic>Brucella<\/jats:italic>\n                      outer membrane protein (Omp) 16, L7\/L12, Omp19 or Cu\u2013Zn SOD proteins has been developed. This paper presents the results of the study of protection of the vaccine using on guinea pigs, including various options of administering, dose and frequency. Provided data of the novel vaccine candidate will contribute to its further movement into the preclinical stage study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      General states of guinea pigs was assessed based on behavior and dynamics of a guinea pig weight-gain test. The effectiveness of the new anti-brucellosis vector vaccine was determined by studying its protective effect after conjunctival, intranasal and sublingual administration in doses 10\n                      <jats:sup>5<\/jats:sup>\n                      EID\n                      <jats:sub>50<\/jats:sub>\n                      , 10\n                      <jats:sup>6<\/jats:sup>\n                      EID\n                      <jats:sub>50<\/jats:sub>\n                      and 10\n                      <jats:sup>7<\/jats:sup>\n                      EID\n                      <jats:sub>50<\/jats:sub>\n                      during prime and boost vaccinations of animals, followed by challenge with a virulent strain of\n                      <jats:italic>B. melitensis<\/jats:italic>\n                      16\u00a0M infection. For sake of comparison, the commercial\n                      <jats:italic>B. melitensis<\/jats:italic>\n                      Rev.1 vaccine was used as a control. The protective properties of vaccines were assessed by quantitation of\n                      <jats:italic>Brucella<\/jats:italic>\n                      colonization in organs and tissues of infected animals and compared to the control groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      It was observed a gradual increase in body weight of guinea pigs after prime and booster immunization with the vaccine using conjunctival, intranasal and sublingual routes of administration, as well as after using various doses of vaccine. The most optimal way of using the vaccine has been established: double intranasal immunization of guinea pigs at a dose of 10\n                      <jats:sup>6<\/jats:sup>\n                      EID\n                      <jats:sub>50<\/jats:sub>\n                      , which provides 80% protection of guinea pigs from\n                      <jats:italic>B. melitensis<\/jats:italic>\n                      16\u00a0M infection (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), which is comparable to the results of the effectiveness of the commercial\n                      <jats:italic>B. melitensis<\/jats:italic>\n                      Rev.1 vaccine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We developed effective human\u00a0vaccine candidate against brucellosis and developed its immunization protocol in guinea pig model. We believe that because of these studies, the proposed vaccine has achieved the best level of protection, which in turn provides a basis for its further promotion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40249-021-00801-y","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T02:38:54Z","timestamp":1613788734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model"],"prefix":"10.1186","volume":"10","author":[{"given":"Dina","family":"Bugybayeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhailaubay","family":"Kydyrbayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Zinina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurika","family":"Assanzhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolat","family":"Yespembetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerken","family":"Kozhamkulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunsulu","family":"Zakarya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-8486","authenticated-orcid":false,"given":"Sholpan","family":"Ryskeldinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaissar","family":"Tabynov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"2","key":"801_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21307\/pjm-2018-029","volume":"67","author":"P G\u0142owacka","year":"2018","unstructured":"G\u0142owacka P, \u017bakowska D, Naylor K, Niemcewicz M, Bielawska-Dr\u00f3zd A. Brucella - virulence factors, pathogenesis and treatment. Pol J Microbiol. 2018;67(2):151\u201361.","journal-title":"Pol J Microbiol"},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.micpath.2019.02.011","volume":"129","author":"M Avijgan","year":"2019","unstructured":"Avijgan M, Rostamnezhad M, Jahanbani-Ardakani H. Clinical and serological approach to patients with brucellosis: a common diagnostic dilemma and a worldwide perspective. Microb Pathog. 2019;129:125\u201330.","journal-title":"Microb Pathog"},{"issue":"22","key":"801_CR3","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMra050570","volume":"352","author":"G Pappas","year":"2005","unstructured":"Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. New Engl J Med. 2005;352(22):2325\u201336.","journal-title":"New Engl J Med"},{"issue":"2","key":"801_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3201\/eid0302.970219","volume":"3","author":"MJ Corbel","year":"1997","unstructured":"Corbel MJ. Brucellosis: an overview. Emerg Infect Dis. 1997;3(2):213\u201321.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"801_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1586\/14787210.6.1.109","volume":"6","author":"JA Al-Tawfiq","year":"2008","unstructured":"Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther. 2008;6(1):109\u201320.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"801_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-117-1-25","volume":"117","author":"J Ariza","year":"1992","unstructured":"Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J, et al. Treatment of human brucellosis with doxycyclin plus rifampicin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med. 1992;117(1):25\u201330.","journal-title":"Ann Intern Med"},{"issue":"3","key":"801_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1574-6976.2010.00211.x","volume":"34","author":"SD Perkins","year":"2010","unstructured":"Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 2010;34(3):379\u201394.","journal-title":"FEMS Microbiol Rev"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1475-2859-5-14","volume":"5","author":"A Miyoshi","year":"2006","unstructured":"Miyoshi A, Berm\u00fadez-Humar\u00e1n LG, Ribeiro LA, et al. Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis. Microb Cell Fact. 2006;5:14.","journal-title":"Microb Cell Fact"},{"issue":"27","key":"801_CR9","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1016\/j.vaccine.2012.04.036","volume":"30","author":"VK Gupta","year":"2012","unstructured":"Gupta VK, Radhakrishnan G, Harms J, Splitter G. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis. Vaccine. 2012;30(27):4017\u201322.","journal-title":"Vaccine"},{"issue":"38","key":"801_CR10","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1016\/j.vaccine.2009.06.075","volume":"27","author":"Z Zhao","year":"2009","unstructured":"Zhao Z, Li M, Luo D, Xing L, Wu S, Duan Y, et al. Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7\/L12 and BLS fusion antigen of Brucella. Vaccine. 2009;27(38):5214\u20139.","journal-title":"Vaccine"},{"issue":"6","key":"801_CR11","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1128\/IAI.73.6.3294-3300.2005","volume":"73","author":"AA O\u00f1ate","year":"2005","unstructured":"O\u00f1ate AA, Donoso G, Moraga-Cid G, Folch H, C\u00e9spedes S, Andrews E. An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu, Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB\/c mice. Infect Immun. 2005;73(6):3294\u2013300.","journal-title":"Infect Immun"},{"issue":"10","key":"801_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/14760584.2016.1208089","volume":"15","author":"K Tabynov","year":"2016","unstructured":"Tabynov K. Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice. Expert Rev Vaccines. 2016;15(10):1237\u20139.","journal-title":"Expert Rev Vaccines"},{"issue":"18","key":"801_CR13","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2014.02.058","volume":"32","author":"K Tabynov","year":"2014","unstructured":"Tabynov K, Kydyrbayev Z, Ryskeldinova S, et al. Novel influenza virus vectors expressing Brucella L7\/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection. Vaccine. 2014;32(18):2034\u201341.","journal-title":"Vaccine"},{"key":"801_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-11-69","volume":"11","author":"K Tabynov","year":"2014","unstructured":"Tabynov K, Sansyzbay A, Kydyrbayev Z, Yespembetov B, Ryskeldinova S, Zinina N, et al. Influenza viral vectors expressing the Brucella OMP16 or L7\/L12 proteins as vaccines against B. abortus infection. Virol J. 2014;11:69.","journal-title":"Virol J."},{"issue":"1","key":"801_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.29252\/IJMR-060103","volume":"6","author":"A Hosseinabadi","year":"2019","unstructured":"Hosseinabadi A, Korani M, Esmaeili D. In silico analysis Brucella OMPs and CagA for expansion of a subunit vaccine candidate versus Brucellosis. IJMR. 2019;6(1):14\u201320.","journal-title":"IJMR"},{"issue":"10","key":"801_CR16","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1093\/nar\/17.10.3757","volume":"17","author":"PA Rice","year":"1989","unstructured":"Rice PA, Steitz TA. Ribosomal protein L7\/L12 has a helix-turn-helix motif similar to that found in DNA-binding regulatory proteins. Nucleic Acids Res. 1989;17(10):3757\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"801_CR17","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1128\/IAI.72.4.2081-2087.2004","volume":"72","author":"C Mu\u00f1oz-Montesino","year":"2004","unstructured":"Mu\u00f1oz-Montesino C, Andrews E, Rivers R, et al. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun. 2004;72(4):2081\u20137.","journal-title":"Infect Immun"},{"key":"801_CR18","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1128\/IAI.67.9.4960-4962.1999","volume":"67","author":"A Tibor","year":"1999","unstructured":"Tibor A, Decelle B, Letesson JJ. Outer membrane proteins Omp10, Omp16, and Omp19 of Brucella spp are lipoproteins. Infect Immun. 1999;67:4960\u20132.","journal-title":"Infect Immun"},{"issue":"1","key":"801_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0378-1119(94)90744-7","volume":"140","author":"SC Oliveira","year":"1994","unstructured":"Oliveira SC, Zhu Y, Splitter GA. Sequence of the rpIJL operon containing L10 and L7\/L12 genes from Brucella abortus. Gene. 1994;140(1):137\u20138.","journal-title":"Gene"},{"issue":"9","key":"801_CR20","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1128\/IAI.58.9.2935-2939.1990","volume":"58","author":"BJ Bricker","year":"1990","unstructured":"Bricker BJ, Tabatabai LB, Judge BA, Deyoe BL, Mayfield JE. Cloning, expression, and occurrence of the Brucella Cu-Zn superoxide dismutase. Infect Immun. 1990;58(9):2935\u20139.","journal-title":"Infect Immun"},{"key":"801_CR21","first-page":"52421","volume":"97","author":"R Brauer","year":"2015","unstructured":"Brauer R, Chen P. Influenza virus propagation in embryonated chicken eggs. J Vis Exp. 2015;97:52421.","journal-title":"J Vis Exp"},{"issue":"23","key":"801_CR22","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMp048267","volume":"351","author":"TT Hien","year":"2004","unstructured":"Hien TT, de Jong M, Farrar J. Avian influenza \u2013 a challenge to global health care structures. N Engl J Med. 2004;351(23):2363\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"801_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/viro.1998.9508","volume":"252","author":"A Garc\u00eda-Sastre","year":"1998","unstructured":"Garc\u00eda-Sastre A, Egorov A, Matassov D, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998;252(2):324\u201330.","journal-title":"Virology"},{"issue":"11","key":"801_CR24","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","volume":"183","author":"IM Belyakov","year":"2009","unstructured":"Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol. 2009;183(11):6883\u201392.","journal-title":"J Immunol"},{"issue":"5","key":"801_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/icb.2016.5","volume":"94","author":"B Clapp","year":"2016","unstructured":"Clapp B, Yang X, Thornburg T, Walters N, Pascual DW. Nasal vaccination stimulates CD8(+) T cells for potent protection against mucosal Brucella melitensis challenge. Immunol Cell Biol. 2016;94(5):496\u2013508.","journal-title":"Immunol Cell Biol"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-021-00801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40249-021-00801-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-021-00801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T02:39:43Z","timestamp":1613788783000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-021-00801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1186\/s40249-021-00801-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-56762\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-56762\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-56762\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-56762\/v1","asserted-by":"object"}]},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"9 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflict of interest was reported by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}